|
Alimera Sciences Inc (NASDAQ: ALIM) |
|
Alimera Sciences Inc
ALIM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Alimera Sciences Inc growth rates, revenue grew
by 52.92 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 959
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.17 %
Alimera Sciences Inc net loss decreased from $-10 millions, to $-3 millions in II. Quarter 2024,
• More on ALIM's Growth
|
|
Alimera Sciences Inc realized a net loss in trailing twelve months.
Alimera Sciences Inc realized cash reduction of $ -0.15 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
• More on ALIM's Valuation
|
|
|
|
|
Alimera Sciences Inc realized net loss in trailing twelve months.
Alimera Sciences Inc realized cash outflow of $ -0.15per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
Alimera Sciences Inc Price to Book Ratio is at 7.77 lower than Industry Avg. of 68.99. and higher than S&P 500 Avg. of 0.01
• More on ALIM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com